The Peptide Field. GHRP-6: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/ghrp-6

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=ghrp-6#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026

Exact product limits: FDA's identity record describes the GHRP-6 molecule, not a finished drug product. FDA lists GHRP-6 in compounding safety reviews and in its current 503A category list. Products sold online or made by a compounder need separate proof of identity, quality, and approval.

Human outcomes: Unclear. Small studies measured short-term hormone responses. They did not establish muscle gain, fat loss, recovery, or other lasting health outcomes.

Body effects in people: Moderate. Small studies in healthy men show a short-term growth-hormone response. One small early study measured how GHRP-6 moved through the body.

What the evidence shows: Small human studies show short-term hormone effects. In 17 healthy men, GHRP-6 increased growth hormone for a short time. Another study in 9 healthy men found that blocking a body signal called GHRH greatly reduced the response. An early study in 9 healthy men measured GHRP-6 exposure in the body. These studies measured hormones and exposure, not muscle gain, fat loss, recovery, or long-term health.

What remains unknown: These studies do not show that GHRP-6 builds muscle, burns fat, speeds recovery, slows aging, or treats a health condition. The studies were small, short, and mainly in healthy men. One study changed the body's GHRH signal to test how the hormone response works. It was not a treatment study. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. This is a dated database finding, not a claim about every country or future record.

Safety limits: FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or aggregation, limited safety information, and possible cortisol or blood-sugar effects. This guide gives no dosing, injection, sourcing, or treatment instructions.

Approval claim: “GHRP-6 is FDA-approved in the United States.”
Verdict: Misleading. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.
Evidence basis: Regulatory or product record. Scope: U.S. human drug records checked on August 30, 2026.
Claim sources: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases https://precision.fda.gov/uniisearch/srs/unii/4H7N4I6X6A

Approval claim: “A compounded GHRP-6 product is FDA-approved.”
Verdict: Misleading. FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.
Evidence basis: Regulatory or product record. Scope: U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.
Claim sources: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act https://www.fda.gov/media/94155/download?attachment= https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019 https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration Global Substance Registration System. GHRP-6 substance identity record (UNII 4H7N4I6X6A). 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/4H7N4I6X6A

PubMed. Growth hormone response to GHRP-6 in healthy men. 1989. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/2543692/

PubMed. GHRP-6 growth hormone response and GHRH dependence. 1998. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/9543138/

PubMed. GHRP-6 exposure study in healthy men. 2012. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/23099431/

U.S. Food and Drug Administration. Drug approvals and databases. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

U.S. Food and Drug Administration. 503A Category 3 bulk drug substances nominated without adequate support. 2026. Accessed 2026-08-30. https://www.fda.gov/media/94155/download?attachment=

U.S. Food and Drug Administration. Bulk drug substances that may present significant compounding safety risks. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. United Pharmacy warning letter. 2019. Accessed 2026-08-30. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019

U.S. Food and Drug Administration. Human drug compounding: FDA questions and answers. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.